Cellebrite DI (NASDAQ:CLBT) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Cellebrite DI (NASDAQ:CLBT) from a buy rating to a hold rating in a report published on Saturday.

Other analysts also recently issued reports about the company. Needham & Company LLC reiterated a “buy” rating and set a $24.00 target price on shares of Cellebrite DI in a research report on Friday, June 6th. JPMorgan Chase & Co. decreased their target price on Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, May 12th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.43.

Cellebrite DI Stock Down 0.4%

Shares of CLBT opened at $13.64 on Friday. The company has a market cap of $3.27 billion, a PE ratio of -14.21, a P/E/G ratio of 2.76 and a beta of 1.27. The business has a fifty day moving average of $15.52 and a 200 day moving average of $18.39. Cellebrite DI has a 52-week low of $11.90 and a 52-week high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.01. The company had revenue of $107.55 million during the quarter, compared to the consensus estimate of $109.36 million. Cellebrite DI had a positive return on equity of 35.36% and a negative net margin of 46.34%. Cellebrite DI’s revenue was up 20.0% on a year-over-year basis. During the same period last year, the company earned $0.08 earnings per share. As a group, research analysts anticipate that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Trading of Cellebrite DI

Several institutional investors and hedge funds have recently made changes to their positions in CLBT. Signaturefd LLC raised its holdings in shares of Cellebrite DI by 68.3% in the second quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock valued at $32,000 after acquiring an additional 819 shares in the last quarter. Assetmark Inc. bought a new stake in shares of Cellebrite DI in the first quarter valued at about $33,000. Catalyst Capital Advisors LLC bought a new stake in shares of Cellebrite DI in the first quarter valued at about $51,000. Virtus Advisers LLC bought a new stake in shares of Cellebrite DI in the first quarter valued at about $63,000. Finally, Hennessy Advisors Inc. bought a new stake in shares of Cellebrite DI in the second quarter valued at about $83,000. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.